Clinical Trial Update: Evaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Knee Arthroplasty [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update indicates PLG0206 is being evaluated in Phase 2/3 to prevent recurrent infection after DAIR in periprosthetic joint infection following kn…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prosthetic Joint Infection

Drugs mentioned

• PLG0206 (PLG0206)

Snippet

Sponsor: Peptilogics | Conditions: Prosthetic-joint Infection | Phase 2, Phase 3 | Status: RECRUITING